Novo Nordisk To Start Phase III Trials Of Hemophilia Contender Concizumab In 2H

 
• By Sten Stovall
  
Hemophilia
Concizumab is a first-in-class recombinant monoclonal antibody that inhibits TFPI • Source: Shutterstock

More from Clinical Trials

More from R&D